<a href="https://laohu8.com/S/FEMY">Femasys Inc</a>. reports nine-month sales of $1.48 million and net loss of $14.68 million
Femasys Inc. reported sales of $1.5 million for the nine months ended September 30, 2025, an increase of 41.3% from $1.0 million in the same period of 2024, driven by sales of FemBloc and FemVue. Research and development expenses decreased 4.7% to $5.8 million from $6.0 million. Net loss for the period was $14.7 million, or ($0.46) per share, compared to a net loss of $13.7 million, or ($0.62) per share, for the prior year period. Cash and cash equivalents totaled $4.6 million at the end of September 2025, up from $3.5 million at the end of 2024. Business developments included a second partner order for FemBloc in Europe, FDA approval to continue the final phase of the FemBloc FINALE trial, and a $12 million financing agreement with potential total funding of $58 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9576107-en) on November 14, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。